The OncoLung Panel is designed to detect mutations within oncogenes and tumor suppressor genes frequently mutated in lung cancers. Diagnostic, prognostic, and predictive biologic markers in this panel are important in personalizing cancer care. The result of this test may guide a patient to the appropriate chemotherapy or clinical trial. The OncoLung Panel is designed to target ~1700 mutations in the following 12 critical lung cancer-related genes: AKT1, ALK, BRAF, EGFR, ERBB2, KRAS, MET, NRAS, PIK3CA, PTEN, STK11 and TP53. 1,2,3,4
To open a printable assay summary in a new window, click the link below.
- Rothberg JM, et al; An integrated semiconducted device enabling non-optical genome sequencing. Nature, 2011 Jul20; 475(7356):348-52
- Dancey JE, et al; The genetic basis for cancer treatment decisions. Cell, 2012 Feb 3; 148(3): 409-20. Review